GLP-1 Antibody (033-10): sc-65389
- GLP-1 Antibody (033-10) is a mouse monoclonal IgG2a provided at 100 µg/ml
- raised against the N-terminus of GLP-1 of human origin
- recommended for detection of GLP-1(7-37) and GLP-1(7-36) amide of human origin by ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for GLP-1 Antibody (033-10). This work is in progress.
GLP-1 Antibody (033-10) is a mouse monoclonal IgG2a antibody that detects glucagon-like peptide-1 (GLP-1) in human samples through enzyme-linked immunosorbent assay (ELISA). GLP-1 plays a crucial role in glucose metabolism and appetite regulation, functioning as an incretin hormone that enhances insulin secretion in response to meals while simultaneously inhibiting glucagon release, thereby lowering blood sugar levels. GLP-1 is primarily produced in the intestinal L-cells and is vital for maintaining glucose homeostasis and promoting satiety, making GLP-1 a significant target for diabetes and obesity research. Additionally, GLP-1 undergoes post-translational modifications, including cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4), which inactivates the hormone and limits therapeutic potential. Understanding these modifications is essential for developing GLP-1-based therapies, as modifications can influence the duration of action and efficacy of GLP-1 receptor agonists used in clinical settings. Anti-GLP-1 antibody (033-10) is an invaluable tool for researchers investigating the intricate roles of GLP-1 in metabolic disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
GLP-1 Antibody (033-10) References:
- Gut microbiota and GLP-1. | Everard, A. and Cani, PD. 2014. Rev Endocr Metab Disord. 15: 189-96. PMID: 24789701
- GLP-1 and Amylin in the Treatment of Obesity. | Jorsal, T., et al. 2016. Curr Diab Rep. 16: 1. PMID: 26699764
- GLP-1 peptide analogs for targeting pancreatic beta cells. | Alavi, SE. and Ebrahimi Shahmabadi, H. 2021. Drug Discov Today. 26: 1936-1943. PMID: 33839290
- GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. | Chen, Y., et al. 2022. Acta Pharmacol Sin. 43: 1156-1166. PMID: 34934197
- The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism. | Danowitz, M. and De Leon, DD. 2022. Front Endocrinol (Lausanne). 13: 863184. PMID: 35399928
- GLP-1 appetite control via intestinofugal neurons. | Spencer, NJ. and Hibberd, TJ. 2022. Cell Res. 32: 711-712. PMID: 35794368
- GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. | Pourkarim, F. and Entezari-Maleki, T. 2023. N Engl J Med. 389: 2303-2304. PMID: 38091542
- GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation. | Zhong, J., et al. 2024. J Pharm Anal. 14: 100917. PMID: 38799233
- Quantifying antihypertensive effects of GLP-1 agonists. | Cohen, JB. and Bress, AP. 2024. Eur Heart J. 45: 4135-4137. PMID: 39217501
- GLP-1 receptor agonists and obesity care. | Franco, JVA. and Manne-Goehler, J. 2024. BMJ. 387: q2732. PMID: 39672568
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GLP-1 Antibody (033-10) | sc-65389 | 100 µg/ml | $322.00 |